Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABCL NASDAQ:COGT NASDAQ:NGNE NASDAQ:PHVS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABCLAbCellera Biologics$4.06+3.0%$2.94$1.89▼$4.46$1.18B0.623.56 million shs7.14 million shsCOGTCogent Biosciences$11.86+3.1%$6.93$3.72▼$12.61$1.31B1.881.60 million shs2.38 million shsNGNENeurogene$22.54+5.0%$18.84$6.88▼$74.49$306.21M1.51252,155 shs89,846 shsPHVSPharvaris$23.00+0.0%$17.61$11.51▼$26.33$1.20B-2.8273,308 shs32,315 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABCLAbCellera Biologics+3.05%-3.79%+28.48%+67.77%+16.33%COGTCogent Biosciences+3.13%+14.04%+58.34%+171.40%+24.84%NGNENeurogene+4.98%+6.02%+18.82%+96.17%-50.73%PHVSPharvaris+0.04%+24.32%+35.61%+64.29%+24.12%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABCLAbCellera Biologics2.1175 of 5 stars3.51.00.00.02.13.30.0COGTCogent Biosciences3.5393 of 5 stars4.43.00.00.02.91.70.6NGNENeurogene3.4127 of 5 stars4.42.00.00.02.72.50.6PHVSPharvaris1.3815 of 5 stars3.51.00.00.01.90.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABCLAbCellera Biologics 3.00Buy$8.75115.52% UpsideCOGTCogent Biosciences 2.82Moderate Buy$18.0051.77% UpsideNGNENeurogene 2.75Moderate Buy$46.17104.82% UpsidePHVSPharvaris 3.00Buy$36.2057.39% UpsideCurrent Analyst Ratings BreakdownLatest NGNE, ABCL, COGT, and PHVS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/14/2025ABCLAbCellera BiologicsKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$5.00 ➝ $10.007/10/2025COGTCogent BiosciencesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$25.00 ➝ $29.007/8/2025COGTCogent BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $22.007/8/2025COGTCogent BiosciencesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.007/8/2025COGTCogent BiosciencesRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$7.00 ➝ $9.007/7/2025ABCLAbCellera BiologicsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy7/7/2025ABCLAbCellera BiologicsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$5.007/7/2025COGTCogent BiosciencesJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$23.00 ➝ $28.007/7/2025COGTCogent BiosciencesLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$16.00 ➝ $18.006/30/2025COGTCogent BiosciencesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral$10.006/17/2025COGTCogent BiosciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABCLAbCellera Biologics$28.83M42.03N/AN/A$3.58 per share1.13COGTCogent BiosciencesN/AN/AN/AN/A$1.32 per shareN/ANGNENeurogene$930K345.61N/AN/A$20.89 per share1.08PHVSPharvarisN/AN/AN/AN/A$5.54 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABCLAbCellera Biologics-$162.86M-$0.56N/AN/AN/A-737.56%-15.98%-12.38%8/7/2025 (Estimated)COGTCogent Biosciences-$255.86M-$1.84N/AN/AN/AN/A-149.79%-75.61%8/5/2025 (Estimated)NGNENeurogene-$75.14M-$4.35N/AN/AN/AN/A-36.16%-32.51%8/8/2025 (Estimated)PHVSPharvaris-$145.24M-$3.01N/AN/AN/AN/A-54.02%-50.36%8/13/2025 (Estimated)Latest NGNE, ABCL, COGT, and PHVS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q1 2025PHVSPharvaris-$0.87N/AN/AN/AN/AN/A8/8/2025Q2 2025NGNENeurogene-$1.15N/AN/AN/AN/AN/A8/7/2025Q2 2025ABCLAbCellera Biologics-$0.17N/AN/AN/A$7.55 millionN/A8/5/2025Q2 2025COGTCogent Biosciences-$0.54N/AN/AN/AN/AN/A5/13/2025Q1 2025PHVSPharvaris-$0.80-$0.89-$0.09-$0.89N/AN/A5/9/2025Q1 2025NGNENeurogene-$1.05-$1.08-$0.03-$1.08N/AN/A5/8/2025Q1 2025ABCLAbCellera Biologics-$0.17-$0.15+$0.02-$0.15$7.12 million$4.24 million5/6/2025Q1 2025COGTCogent Biosciences-$0.56-$0.52+$0.04-$0.52N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABCLAbCellera BiologicsN/AN/AN/AN/AN/ACOGTCogent BiosciencesN/AN/AN/AN/AN/ANGNENeurogeneN/AN/AN/AN/AN/APHVSPharvarisN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABCLAbCellera BiologicsN/A10.1510.15COGTCogent BiosciencesN/A5.135.13NGNENeurogeneN/A21.0321.03PHVSPharvarisN/A11.1011.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABCLAbCellera Biologics61.42%COGTCogent BiosciencesN/ANGNENeurogene52.37%PHVSPharvarisN/AInsider OwnershipCompanyInsider OwnershipABCLAbCellera Biologics28.90%COGTCogent Biosciences7.29%NGNENeurogene11.64%PHVSPharvaris11.84%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABCLAbCellera Biologics500298.42 million212.18 millionOptionableCOGTCogent Biosciences80113.86 million105.56 millionOptionableNGNENeurogene9014.26 million12.60 millionOptionablePHVSPharvaris3052.29 million46.10 millionNot OptionableNGNE, ABCL, COGT, and PHVS HeadlinesRecent News About These CompaniesPharvaris (NASDAQ:PHVS) Stock Price Down 5.9% - Here's What HappenedJuly 15 at 4:23 PM | marketbeat.comPharvaris (NASDAQ:PHVS) Sees Unusually-High Trading Volume - Time to Buy?July 14 at 12:28 PM | marketbeat.comBank of America Securities Reaffirms Their Sell Rating on Pharvaris (PHVS)July 12, 2025 | theglobeandmail.comPharvaris (NASDAQ:PHVS) Reaches New 1-Year High - Here's What HappenedJuly 12, 2025 | marketbeat.comPharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 ...July 11, 2025 | morningstar.comMPharvaris Updates Timing of Topline Data ... - The Manila TimesJuly 11, 2025 | manilatimes.netMPharvaris (NASDAQ:PHVS) Stock Price Up 9.9% - Time to Buy?July 11, 2025 | marketbeat.comPharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025July 10, 2025 | globenewswire.comBrokerages Set Pharvaris N.V. (NASDAQ:PHVS) PT at $36.20July 9, 2025 | americanbankingnews.comPharvaris N.V. (NASDAQ:PHVS) Receives Consensus Rating of "Buy" from BrokeragesJuly 6, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Shares Gap Up - What's Next?July 3, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Trading Down 4.9% - What's Next?June 27, 2025 | marketbeat.comPharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National SummitJune 27, 2025 | globenewswire.comPharvaris N.V. (9EN.F) stock price, news, quote & history - Yahoo FinanceJune 26, 2025 | sg.finance.yahoo.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Bristol-Myers Squibb (BMY) and Pharvaris (PHVS)June 24, 2025 | theglobeandmail.comPharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat ...June 16, 2025 | gurufocus.comPharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat ...June 16, 2025 | gurufocus.comPharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the EAACI CongressJune 16, 2025 | globenewswire.comPharvaris Announces 2025 Annual Shareholders Meeting Amidst Phase 3 TrialsJune 10, 2025 | tipranks.comPharvaris Announces Annual Meeting of ShareholdersJune 10, 2025 | globenewswire.comPharvaris’s Deucrictibant: Expanding Market Reach in Bradykinin-Mediated Angioedemas with Promising Phase 3 TrialsJune 5, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNGNE, ABCL, COGT, and PHVS Company DescriptionsAbCellera Biologics NASDAQ:ABCL$4.06 +0.12 (+3.05%) Closing price 07/16/2025 04:00 PM EasternExtended Trading$4.08 +0.02 (+0.37%) As of 07/16/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.Cogent Biosciences NASDAQ:COGT$11.86 +0.36 (+3.13%) Closing price 07/16/2025 04:00 PM EasternExtended Trading$11.86 0.00 (0.00%) As of 07/16/2025 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.Neurogene NASDAQ:NGNE$22.54 +1.07 (+4.98%) Closing price 07/16/2025 04:00 PM EasternExtended Trading$22.55 +0.01 (+0.04%) As of 07/16/2025 04:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.Pharvaris NASDAQ:PHVS$23.00 +0.01 (+0.04%) Closing price 07/16/2025 04:00 PM EasternExtended Trading$22.94 -0.07 (-0.28%) As of 07/16/2025 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD Just Triggered a Signal Traders Can’t Ignore JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out Rocket Lab Gets New Street-High Price Target from Citi Super Micro Stock May Benefit as Cooling Demand Takes Off Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings Salesforce Stock Set for 30% Upside to Reach New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
